MDT-AP-2167
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 119.52000000000001
- os_event
- false
- age_years
- 1
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.515069655
- umap2_2d
- -9.000752128
- umap1_3d
- -3.650165317
- umap2_3d
- -1.439223815
- umap3_3d
- 5.278953752
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INFLAMMATORY_RESPONSE+0.370
- ALLOGRAFT_REJECTION+0.340
- IL6_JAK_STAT3_SIGNALING+0.340
- NOTCH_SIGNALING+0.330
- UV_RESPONSE_DN+0.300
- E2F_TARGETS+0.280
- TNFA_SIGNALING_VIA_NFKB+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.260
- PI3K_AKT_MTOR_SIGNALING-0.190
- DNA_REPAIR-0.180
- HEME_METABOLISM-0.180
- UNFOLDED_PROTEIN_RESPONSE-0.140
- MITOTIC_SPINDLE-0.090
- WNT_BETA_CATENIN_SIGNALING-0.080
- PEROXISOME-0.050
- FATTY_ACID_METABOLISM-0.020
- MTORC1_SIGNALING-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0815 | Med | Medulloblastoma | 0.880 |
| 2 | MDT-AP-2902 | Med | Medulloblastoma | 0.859 |
| 3 | MDT-AP-2990 | Med | Medulloblastoma | 0.855 |
| 4 | MDT-AP-2284 | Med | Medulloblastoma | 0.846 |
| 5 | MDT-AP-2131 | Med | Medulloblastoma | 0.844 |
| 6 | BS_J1AB8PMA | Med | Medulloblastoma | 0.833 |
| 7 | MDT-AP-2377 | Med | Medulloblastoma | 0.823 |
| 8 | MDT-AP-2921 | Med | Medulloblastoma | 0.822 |
| 9 | MDT-AP-2910 | Med | Medulloblastoma | 0.822 |
| 10 | DRR168605 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |